| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8b9036c33bbe3f4ea428655b76200f7c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-734
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2002-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49cf351d603bd4d87986629ec9a3f6fa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0688d4c158c96b28a6c262705b53e0da
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c77936fce552d2606835f91c46d9f71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c98aaebebfc912853930a97d7a13ff23 |
| publicationDate |
2007-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1384487-A4 |
| titleOfInvention |
MEDICAMENTS CONTAINING A GENETICALLY MODIFIED ANTIBODY AGAINST GD3 GANGLIOSIDE |
| abstract |
It has been required to establish a highly efficacious therapeutic method for malignant tumor, in particular melanoma, with little side effects and a novel therapeutic method whereby an enhanced therapeutic effect can be achieved in a conventional drug dose. By combining a genetically modified antibody against ganglioside GD3 or its fragment with at least one of a substance capable of activating immunocompetent cells and a substance having an antitumor activity, it is intended to provide drugs having an enhanced therapeutic effect compared with the case of administering either the substance capable of activating immunocompetent cells or the substance having an antitumor activity alone. It is expected that these drugs can relieve the problem of side effects occurring in the conventional single administration. |
| priorityDate |
2001-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |